Transanal endoscopic microsurgery with alternative neoadjuvant imatinib for localized rectal gastrointestinal stromal tumor: a single center experience with long-term surveillance

被引:9
作者
Bai, Xueshan [1 ]
Zhou, Weixun [2 ]
Li, Yunhao [1 ]
Lin, Guole [1 ]
机构
[1] Chinese Acad Med Sci, Dept Gen Surg, Peking Union Med Coll Hosp, Peking Union Med Coll, 1 Shuai Fu Yuan, Beijing 100730, Peoples R China
[2] Chinese Acad Med Sci, Dept Pathol, Peking Union Med Coll Hosp, Peking Union Med Coll, 1 Shuai Fu Yuan, Beijing 100730, Peoples R China
来源
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES | 2021年 / 35卷 / 07期
关键词
Rectal lesion; Transanal endoscopic microsurgery; Gastrointestinal stromal tumors; Imatinib; FOLLOW-UP; THERAPY; MESYLATE; RESECTION; SURGERY; RISK; ERA;
D O I
10.1007/s00464-020-07837-5
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background Transanal endoscopic microsurgery (TEM) is widely used in the treatment of local rectal lesions and helps avoid radical surgery. This study evaluated the management and outcome in a long-term followed cohort of patients with localized rectal GIST underwent TEM with alternative neodajuvant imatinib (nIM). Methods A retrospective cohort study was undertaken of patients identified from a case database at Department of General Surgery, Peking Union Medical College Hospital (PUMCH) over a continuous period, from January 2006 to December 2017. Results Over 12 years, 42 patients presented with a primary rectal GIST in PUMCH. Median age was 49 (range 27-77) years. Neoadjuvant imatinib (nIM) therapy was used in 16 patients, significantly reducing mean tumor size from 4.41 to 2.46 cm (p < 0.001) and mitotic index (p = 0.041). All of these patients underwent TEM with no tumor rupture, nIM therapy enabled sphincter-preserving surgery to be undertaken in 16 (16/42) patients who would otherwise have required abdominoperineal resection or pelvic exenteration for tumor clearance and all patients (42/42) achieve RO resection and negative margin. Imatinib was also used as postoperative adjuvant treatment in 15 patients with high-risk GIST. Median follow-up was 77 (range 14-144) and overall survival is 100%. In 42 patients, Local recurrence (LR) occurred in 3 of 42 patients and 1 of 42 patients developed distant metastasis (DM) in 112 months after TEM. In the univariate analysis, mitotic index (p = 0.028), NIH risk categories (p = 0.047) were predictive feature of local relapse. Conclusion The application of nIM significantly decreased tumor size in large localized rectal GIST, which permitted TEM to preserve sphincter. The TEM procedure with alternative neoadjuvant imatinib therapy is a practicable treatment for patients with rectal GIST to preserve anus and have satisfied anal function.
引用
收藏
页码:3607 / 3617
页数:11
相关论文
共 27 条
  • [1] [Anonymous], 2019, NCCN CLIN PRACTICE G
  • [2] 백옥주, 2009, Annals of Coloproctolgy, V25, P318
  • [3] BUESS G, 1983, LEBER MAGEN DARM, V13, P73
  • [4] Transanal endoscopic microsurgical excision of rectal tumors:: Indications and results
    Demartines, N
    von Flüe, MO
    Harder, FH
    [J]. WORLD JOURNAL OF SURGERY, 2001, 25 (07) : 870 - 875
  • [5] Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
    DeMatteo, Ronald P.
    Ballman, Karla V.
    Antonescu, Cristina R.
    Maki, Robert G.
    Pisters, Peter W. T.
    Demetri, George D.
    Blackstein, Martin E.
    Blanke, Charles D.
    von Mehren, Margaret
    Brennan, Murray F.
    Patel, Shreyaskumar
    McCarter, Martin D.
    Polikoff, Jonathan A.
    Tan, Benjamin R.
    Owzar, Kouros
    [J]. LANCET, 2009, 373 (9669) : 1097 - 1104
  • [6] DOWNSTAGING OF A RECTAL GASTROINTESTINAL STROMAL TUMOR BY NEOADJUVANT IMATINIB THERAPY ALLOWING FOR A CONSERVATIVE SURGICAL APPROACH
    Fernandes, Gustavo dos Santos
    de Castro Cotti, Guilherme Cutait
    Freitas, Daniela
    Cutait, Raul
    Hoff, Paulo M.
    [J]. CLINICS, 2009, 64 (08) : 819 - 821
  • [7] Diagnosis of gastrointestinal stromal tumors: A consensus approach
    Fletcher, CDM
    Berman, JJ
    Corless, C
    Gorstein, F
    Lasota, J
    Longley, BJ
    Miettinen, M
    O'Leary, TJ
    Remotti, H
    Rubin, BP
    Shmookler, B
    Sobin, LH
    Weiss, SW
    [J]. HUMAN PATHOLOGY, 2002, 33 (05) : 459 - 465
  • [8] Incidence of gastrointestinal stromal tumours is underestimated: Results of a nation-wide study
    Goettsch, WG
    Bos, SD
    Breekveldt-Postma, N
    Casparie, M
    Herings, RMC
    Hogendoorn, PCW
    [J]. EUROPEAN JOURNAL OF CANCER, 2005, 41 (18) : 2868 - 2872
  • [9] Hohenberger P, 2009, J CLIN ONCOL, V27, P548
  • [10] Gastrointestinal Stromal Tumor of the Rectum: Results of Surgical and Multimodality Therapy in the Era of Imatinib
    Jakob, Jens
    Mussi, Chiara
    Ronellenfitsch, Ulrich
    Wardelmann, Eva
    Negri, Tiziana
    Gronchi, Alessandro
    Hohenberger, Peter
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (02) : 586 - 592